Perceptic
Pharmaceutical AI operating system startup founded by an ex-Palantir team; raised $12m seed on 27 May 2026.
Last refreshed: 29 May 2026 · Appears in 1 active topic
Can an ex-Palantir team unify drug discovery and clinical trials on a single AI platform?
What does Perceptic do and how does its AI platform work for drug development?
Who are the founders of Perceptic and where did they work before?
How much has Perceptic raised and who backed it?
Background
Perceptic emerged from stealth on 27 May 2026 with a $12m seed round led by Accel, with Air Street Capital and Elder Gull participating. The company, founded by three former Palantir executives who built Palantir's life sciences commercial practice, is building an end-to-end AI platform for drug development: covering drug discovery, candidate optimisation, clinical trial design and regulatory submission in a single operating environment.
Co-founders Tilman Flock (CEO), Zaki Trache and Martin Copes collectively spent years at Palantir building AI deployments for pharmaceutical clients before identifying the lack of integrated tooling as the primary barrier to faster drug development. Perceptic's software was in use with multiple top-tier pharmaceutical companies at launch, with CSL — the Australian biotech — named as a disclosed customer. The bulk of seed funding is directed at engineering and customer growth.
Perceptic enters a crowded but fragmented AI-in-pharma market. Its differentiation is the operating-system framing — positioning the platform as workflow infrastructure rather than a point solution for any single stage of drug development. The Accel backing and Palantir pedigree give it credibility in enterprise pharma procurement, where institutional trust is the primary sales blocker.